Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

Blood

Volumn 115, Issue 12, 2010, Pages 2364-2371

  Pennell, Dudley J ^a   Porter, John B ^b   Cappellini, Maria Domenica ^c   El Beshlawy, Amal ^d   Chan, Lee Lee ^e   Aydinok, Yesim ^f   Elalfy, Mohsen Saleh ^g   Sutcharitchan, Pranee ^h   Li, Chi Kong ⁱ   Ibrahim, Hishamshah ^j   Viprakasit, Vip ^k   Kattamis, Antonis ^l   Smith, Gillian ^a   Habr, Dany ^m   Domokos, Gabor ^m   Roubert, Bernard ^m   Taher, Ali ⁿ  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MILAN   (Italy)

^d CAIRO UNIVERSITY   (Egypt)

^e UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^f EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^g AIN SHAMS UNIVERSITY   (Egypt)

^h CHULALONGKORN UNIVERSITY   (Thailand)

ⁱ CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^j HOSPITAL KUALA LUMPUR   (Malaysia)

^k MAHIDOL UNIVERSITY   (Thailand)

^l UNIVERSITY OF ATHENS   (Greece)

^m NOVARTIS PHARMA AG   (Switzerland)

ⁿ AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; FERRITIN; BENZOIC ACID DERIVATIVE; IRON; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; APPENDICITIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BETA THALASSEMIA; CARDIOMYOPATHY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; FEVER; GASTROINTESTINAL DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE; HEPATITIS C; HUMAN; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SKIN DISEASE; ULCERATIVE COLITIS; ADOLESCENT; BLOOD; CHILD; DOSE RESPONSE; HEART FAILURE; METABOLISM; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; BENZOIC ACIDS; BETA-THALASSEMIA; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FERRITINS; HEART FAILURE; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MYOCARDIUM; PROSPECTIVE STUDIES; TRIAZOLES; YOUNG ADULT;

EID: 77950617863     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-04-217455     Document Type: Article

References (41)

1. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567-573.
2. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2(8653):27-30. (Pubitemid 19158169)
3. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331(9):574-578. (Pubitemid 24265699)
4. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193. (Pubitemid 39390442)
5. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998;850:227-231. (Pubitemid 28369763)
6. Tanner MA, Galanello R, Dessi C, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson. 2006;8(3):543-547.
7. Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008;112(7):2973-2978.
8. Ludwiczek S, Theurl I, Muckenthaler MU, et al. Ca2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1. Nat Med. 2007;13(4):448-454. (Pubitemid 46562464)
9. Oudit GY, Sun H, Trivieri MG, et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003;9(9):1187-1194. (Pubitemid 37173704)
10. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171-2179. (Pubitemid 33139463)
11. He T, Kirk P, Firmin DN, et al. Multi-center transferability of a breath-hold T2 technique for myocardial iron assessment. J Cardiovasc Magn Reson. 2008;10(1):11.
12. Wood JC, Otto-Duessel M, Aguilar M, et al. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation. 2005;112(4):535-543. (Pubitemid 41060794)
13. Carpenter JP, He T, Kirk P, et al. Calibration of myocardial iron concentration against T2-star cardiovascular magnetic resonance [abstract]. J Cardiovasc Magn Reson. 2009;11(suppl 1):P224.
14. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103(5):1934-1936. (Pubitemid 38268994)
15. Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961-1968.
16. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10(1):42.
17. Westwood M, Anderson LJ, Firmin DN, et al. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging. 2003;18(1):33-39. (Pubitemid 36791266)
18. Westwood MA, Anderson LJ, Firmin DN, et al. Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia. J Magn Reson Imaging. 2003;18(5):616-620.
19. Westwood MA, Firmin DN, Gildo M, et al. Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia. Int J Cardiovasc Imaging. 2005;21(5):531-538. (Pubitemid 41435154)
20. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006;107(9):3455-3462.
21. Vichinsky E, Onyekwere O, Porter J, et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501-508. (Pubitemid 46046309)
22. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168-176.
23. Wood JC, Otto-Duessel M, Gonzales I, et al. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res. 2006;148(5):272-280. (Pubitemid 44634299)
24. Cappellini MD, Porter JB, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin trends: prospective EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias. Haematologica. Prepublished on November 30, 2009, as DOI 10.3324/haematol.2009.014696.
25. He T, Gatehouse PD, Smith GC, Mohiaddin RH, Pennell DJ, Firmin DN. Myocardial T2* measurements in iron-overloaded thalassemia: an in vivo study to investigate optimal methods of quantification. Magn Reson Med. 2008;60(5):1082-1089.
26. Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2006;8(3):417-426.
27. Maceira AM, Prasad SK, Khan M, Pennell DJ. Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance. Eur Heart J. 2006;27(23):2879-2888. (Pubitemid 44871471)
28. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855-861. (Pubitemid 40070775)
29. St Pierre TG, Clark PR, Chua-anusorn W. Single spin-echo proton transverse relaxometry of iron-loaded liver. NMR Biomed. 2004;17(7):446-458. (Pubitemid 39549422)
30. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738-3744.
31. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876-1884. (Pubitemid 46598901)
32. Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. 2008;10(1):12.
33. Glickstein H, El RB, Link G, et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood. 2006;108(9):3195-3203.
34. Kakhlon O, Manning H, Breuer W, et al. Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Blood. 2008;112(13):5219-5227.
35. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann N Y Acad Sci. 2005;1054:40-47.
36. Reyal Y, Chowdhury O, Kirk P, Prescott E, Davis B, Shah F. Improvement in cardiac T2* with deferasirox in transfused patients with cardiac iron overload [abstract]. Haematologica. 2008;93(suppl 1):846.
37. Vichinsky E, Pakbaz Z, Onyekwere O, et al. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis: substudy of a randomized open-label phase II trial. Acta Haematol. 2008;119(3):133-141. (Pubitemid 351896547)
38. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with betathalassemia. Clin Ther. 2007;29(5):909-917. (Pubitemid 47241173)
39. Taher A, Al Jefri A, Elalfy M, et al. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with betathalassemia: results from ESCALATOR trial [abstract]. Haematologica. 2008;9(suppl 1):799.
40. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009;147(5):752-759.
41. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood. 2008;111(2):583-587.